Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

NIH 3INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 3Thoracic 3Gastrointestinal 3Genitourinary 2Sarcoma 1NET 1Head & Neck 1Endocrine 1Breast 1

Conditions

Prostatic Neoplasms 2

Interventions

pembrolizumab 164Prednisone 130enzalutamide 127Docetaxel 123Abiraterone Acetate 95Nivolumab 93Gemcitabine 71Sunitinib 67abiraterone 51atezolizumab 50Leuprolide 49acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 48Cisplatin 48radium Ra 223 dichloride 39darolutamide 39Sorafenib 39apalutamide 38Ipilimumab 38Carboplatin 37Prednisolone 33Everolimus 33Axitinib 32cabozantinib 31avelumab 31pazopanib 30Bevacizumab 30Paclitaxel 29enfortumab vedotin 28bicalutamide 28Cyclophosphamide 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × cixutumumab × Genitourinary × Clear all
NCT00520481 2018-07-19

Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer

Eli Lilly and Company

Phase 2 Completed
41 enrolled 14 charts
Genitourinary

Prostatic Neoplasms

NCT00683475 2014-10-16

A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer

Eli Lilly and Company

Phase 2 Completed
138 enrolled 17 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡